Scholarlink

Objective <p>Evaluate associations between antenatal exposure to medication for opioid use disorder (MOUD), including MOUD type, and neonatal outcomes for infants with neonatal opioid withdrawal syndrome (NOWS).</p> Study design <p>Data from 768 neonates with NOWS born between 36-0/7 to 41-6/7 weeks gestation were retrospectively collected from 13 United States hospitals.</p> Results <p>Compared to neonates with antenatal exposure to non-MOUD opioids, neonates with antenatal exposure to MOUD opioids had a 51% lower odds of delivery before 39 weeks and 2.72-fold greater odds of breastfeeding. Compared to neonates with antenatal exposure to prescribed methadone, neonates exposed to prescribed buprenorphine or buprenorphine/naloxone had increased mean head circumference z-scores (0.31 and 0.48 units respectively), decreased odds of pharmacologic treatment (49% and 58%, respectively), and a reduced mean length of hospital stay (35% and 39%, respectively).</p> Conclusion <p>Antenatal exposure to MOUD opioids, specifically prescribed buprenorphine, was associated with significantly improved neonatal outcomes.</p> ClinicalTrials.gov ID <p>INFORM NOW: N/A</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between medication for opioid use disorder during pregnancy and neonatal outcomes

  • 期刊论文

  • 发表日期：

    2025年10月9日

查看全文
  • Richard W. Hall,
  • Denise C. Babineau,
  • Ananta S. Bangdiwala,
  • Evan Rhodes,
  • Tara Venable,
  • Clare Campbell Asher,
  • Namasivayam Ambalavanan,
  • Jonathan M. Davis,
  • Susan Adeniyi-Jones,
  • Lawrence Leeman,
  • Abhik Das,
  • Margaret Crawford,
  • Lillian Trochinski,
  • Stephanie Merhar,
  • Gregory M. Sokol,
  • Scott A. Lorch,
  • Lori A. Devlin

摘要

Objective

Evaluate associations between antenatal exposure to medication for opioid use disorder (MOUD), including MOUD type, and neonatal outcomes for infants with neonatal opioid withdrawal syndrome (NOWS).

Study design

Data from 768 neonates with NOWS born between 36-0/7 to 41-6/7 weeks gestation were retrospectively collected from 13 United States hospitals.

Results

Compared to neonates with antenatal exposure to non-MOUD opioids, neonates with antenatal exposure to MOUD opioids had a 51% lower odds of delivery before 39 weeks and 2.72-fold greater odds of breastfeeding. Compared to neonates with antenatal exposure to prescribed methadone, neonates exposed to prescribed buprenorphine or buprenorphine/naloxone had increased mean head circumference z-scores (0.31 and 0.48 units respectively), decreased odds of pharmacologic treatment (49% and 58%, respectively), and a reduced mean length of hospital stay (35% and 39%, respectively).

Conclusion

Antenatal exposure to MOUD opioids, specifically prescribed buprenorphine, was associated with significantly improved neonatal outcomes.

ClinicalTrials.gov ID

INFORM NOW: N/A